Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer

This series is intended to improve care of patients with non-small cell lung cancer and head & neck cancer by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

FACULTY

John V. Heymach, MD, PhD
Professor and Chair
Department of Thoracic/Head and Neck
  Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson
  Cancer Center
Houston, TX

Jianjun Zhang, MD, PhD
Assistant Professor
Department of Thoracic/Head and Neck
  Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson
  Cancer Center
Houston, TX

Anne Tsao, MD
Professor
Department of Thoracic/Head and Neck
  Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson
  Cancer Center
Houston, TX

Vincent Lam, MD
Assistant Professor
Department of Thoracic/Head and Neck
  Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson
  Cancer Center
Houston, TX

Jointly provided by

These activities are supported by educational grants from
Merck Sharp & Dohme Corp., AstraZeneca Pharmaceuticals LP, and Bristol-Myers Squibb Company.